India · Delayed Price · Currency is INR Nath Bio-Genes (India) Statistics
Total Valuation
NSE:NATHBIOGEN has a market cap or net worth of INR 3.25 billion. The enterprise value is 3.88 billion.
| Market Cap | 3.25B |
| Enterprise Value | 3.88B |
Important Dates
The last earnings date was Monday, May 4, 2026.
| Earnings Date | May 4, 2026 |
| Ex-Dividend Date | Aug 14, 2025 |
Share Statistics
NSE:NATHBIOGEN has 19.00 million shares outstanding. The number of shares has increased by 4.41% in one year.
| Current Share Class | 19.00M |
| Shares Outstanding | 19.00M |
| Shares Change (YoY) | +4.41% |
| Shares Change (QoQ) | +17.02% |
| Owned by Insiders (%) | 10.76% |
| Owned by Institutions (%) | 2.23% |
| Float | 6.05M |
Valuation Ratios
The trailing PE ratio is 8.16.
| PE Ratio | 8.16 |
| Forward PE | n/a |
| PS Ratio | 0.73 |
| PB Ratio | 0.48 |
| P/TBV Ratio | 0.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 7.40, with an EV/FCF ratio of -24.90.
| EV / Earnings | 9.32 |
| EV / Sales | 0.87 |
| EV / EBITDA | 7.40 |
| EV / EBIT | 8.00 |
| EV / FCF | -24.90 |
Financial Position
The company has a current ratio of 1.97, with a Debt / Equity ratio of 0.20.
| Current Ratio | 1.97 |
| Quick Ratio | 0.41 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | 2.64 |
| Debt / FCF | -8.89 |
| Interest Coverage | 3.04 |
Financial Efficiency
Return on equity (ROE) is 6.28% and return on invested capital (ROIC) is 5.53%.
| Return on Equity (ROE) | 6.28% |
| Return on Assets (ROA) | 2.85% |
| Return on Invested Capital (ROIC) | 5.53% |
| Return on Capital Employed (ROCE) | 6.90% |
| Weighted Average Cost of Capital (WACC) | 9.68% |
| Revenue Per Employee | 9.87M |
| Profits Per Employee | 923,067 |
| Employee Count | 451 |
| Asset Turnover | 0.42 |
| Inventory Turnover | 0.51 |
Taxes
In the past 12 months, NSE:NATHBIOGEN has paid 46.73 million in taxes.
| Income Tax | 46.73M |
| Effective Tax Rate | 10.09% |
Stock Price Statistics
The stock price has increased by +7.29% in the last 52 weeks. The beta is 0.93, so NSE:NATHBIOGEN's price volatility has been similar to the market average.
| Beta (5Y) | 0.93 |
| 52-Week Price Change | +7.29% |
| 50-Day Moving Average | 154.24 |
| 200-Day Moving Average | 161.39 |
| Relative Strength Index (RSI) | 53.21 |
| Average Volume (20 Days) | 75,191 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:NATHBIOGEN had revenue of INR 4.45 billion and earned 416.30 million in profits. Earnings per share was 20.98.
| Revenue | 4.45B |
| Gross Profit | 2.44B |
| Operating Income | 484.75M |
| Pretax Income | 463.04M |
| Net Income | 416.30M |
| EBITDA | 524.39M |
| EBIT | 484.75M |
| Earnings Per Share (EPS) | 20.98 |
Balance Sheet
The company has 759.95 million in cash and 1.39 billion in debt, with a net cash position of -625.06 million or -32.89 per share.
| Cash & Cash Equivalents | 759.95M |
| Total Debt | 1.39B |
| Net Cash | -625.06M |
| Net Cash Per Share | -32.89 |
| Equity (Book Value) | 6.80B |
| Book Value Per Share | 304.35 |
| Working Capital | 3.84B |
Cash Flow
In the last 12 months, operating cash flow was -125.73 million and capital expenditures -30.05 million, giving a free cash flow of -155.78 million.
| Operating Cash Flow | -125.73M |
| Capital Expenditures | -30.05M |
| Depreciation & Amortization | 39.64M |
| Net Borrowing | 160.01M |
| Free Cash Flow | -155.78M |
| FCF Per Share | -8.20 |
Margins
Gross margin is 54.73%, with operating and profit margins of 10.89% and 9.35%.
| Gross Margin | 54.73% |
| Operating Margin | 10.89% |
| Pretax Margin | 10.40% |
| Profit Margin | 9.35% |
| EBITDA Margin | 11.78% |
| EBIT Margin | 10.89% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 2.00, which amounts to a dividend yield of 1.15%.
| Dividend Per Share | 2.00 |
| Dividend Yield | 1.15% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 9.13% |
| Buyback Yield | -4.41% |
| Shareholder Yield | -3.28% |
| Earnings Yield | 12.79% |
| FCF Yield | -4.79% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |